SPY337.76-8.02 -2.32%
DIA275.43-7.91 -2.79%
IXIC11,303.07-245.22 -2.12%

Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy

AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months • 21-point mean improvement in UPDRS Part III “OFF” score, a 40% improvement from baseline, exceeding

· 10/06/2020 07:03

AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months
• 21-point mean improvement in UPDRS Part III “OFF” score, a 40% improvement from baseline, exceeding pre-defined criteria for success
• Greater than 2-hour improvement from baseline in both diary “good ON time and diary OFF time assessments
• EXPLORE-PD, a randomized, sham-controlled study of AXO-Lenti-PD is expected to begin dosing in 2021